Keros Therapeutics (KROS) Cash from Operations (2019 - 2025)

Keros Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 27292000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations rose 40.68% year-over-year to 27292000.0; the trailing twelve-month figure through Dec 2025 stood at 107505000.0 (up 166.83% YoY), and the FY2025 full-year result was 107505000.0, up 166.83% from the prior year.
• Cash from Operations for Q4 2025 stood at 27292000.0, down from 3249000.0 in the prior quarter.
• The five-year high for Cash from Operations was 161171000.0 in Q1 2025, with the low at 46008000.0 in Q4 2024.
• Historically, Cash from Operations has averaged 15504100.0 across 5 years, with a median of 25030500.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Operations plunged 2299.09% — and 2025, when it jumped 461.69%.
• Keros Therapeutics' Cash from Operations stood at 19565000.0 in 2021, then slipped by 9.6% to 21443000.0 in 2022, then fell by 18.73% to 25459000.0 in 2023, then sank by 80.71% to 46008000.0 in 2024, then surged by 40.68% to 27292000.0 in 2025.
• The last three Cash from Operations figures came in at 27292000.0 (Q4 2025), 3249000.0 (Q3 2025), and 29623000.0 (Q2 2025), per Business Quant data.